Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease

Movement Disorders

Volumn 28, Issue 14, 2013, Pages 2007-2010

  Catalán, María José ^a   de Pablo Fernández, Eduardo ^a   Villanueva, Clara ^a   Fernández Diez, Servando ^a   Lapeña Montero, Teresa ^a   García Ramos, Rocío ^a   López Valdés, Eva ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

DDS; Impulse control disorders; Infusion pumps; Intraduodenal levodopa; Levodopa, administration and dosage; Parkinson's disease

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIPARKINSON AGENT; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; CLOZAPINE; ENTACAPONE; ESCITALOPRAM; LEVODOPA; METHYLPHENIDATE; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SERTRALINE; TOPIRAMATE;

ADULT; AGED; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE DYSREGULATION SYNDROME; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; IMPULSE CONTROL DISORDER; IMPULSIVENESS; INTRAJEJUNAL DRUG ADMINISTRATION; JEJUNAL LEVODOPA INFUSION; MALE; PARKINSON DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

DDS; IMPULSE CONTROL DISORDERS; INFUSION PUMPS; INTRADUODENAL LEVODOPA; LEVODOPA, ADMINISTRATION AND DOSAGE; PARKINSON'S DISEASE;

AGED; ANTIPARKINSON AGENTS; DOPAMINE; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84889652783     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25636     Document Type: Article

References (18)

1. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009;24:1561-1570.
2. Weintraub D, Koester J, Pontenza MN, et al. Impulse control disorders in Parkinson's disease. Arch Neurol 2010;67:589-595.
3. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson. Neurology 2005;65:1570-1574.
4. Djamshidian A, Averbeck BB, Lees AJ, O'Sullivan SS. Clinical aspects of impulsive compulsive behaviours in Parkinson's disease. J Neurol Sci 2011;310:183-188.
5. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
6. Olanow CW, Antonini A, Kieburtz K, et al. Randomized, double-blind, double-dummy study of continuous infusion of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: efficacy and safety. Mov Disord 2012;27:S1-S595.
7. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
8. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008;29(Suppl 5):S387-S388.
9. Gerschlager W, Bloem BR. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions. Mov Disord 2009;24:1858-1860.
10. Valldeoriola F, Cámara A. Intraduodenal infusion of levodopa. Rev Neurol 2010;51:41-48.
11. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord 2003;18:467-486.
12. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
13. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009;8:1140-1149.
14. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009;132:1376-1385.
15. van Eimeren T, Pellecchia G, Cilia R, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010;75:1711-1716.
16. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
17. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
18. Cannas A, Solla P, Marrosu MG, Marrosu F. Dopamine dysregulation syndrome in Parkinson's disease patients on duodenal levodopa infusion. Mov Disord 2013;28:840-841.